Evidence map›Paper›PMID 41825652›Full record

ArticleBrain, behavior, and immunity2026

Sex-specific gut mycobiome dysbiosis activates macrophage dectin-1 signaling to drive neurobehavioral deficits in EcoHIV-infected mice.

Yannan Li, Shinji Sakamoto, Matthew D Smith, Yuto Hasegawa, Meixiang Huang, Naigang Li, Manjot Dhaliwal, Tessa Schauermann, Feiyi Xiong, Bin Luo and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yannan LiPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shinji SakamotoDepartment of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Matthew D SmithDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yuto HasegawaPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Meixiang HuangDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Naigang LiPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Manjot DhaliwalPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tessa SchauermannPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Feiyi XiongPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bin LuoPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
Hui LiSchool of Electrical, Computer and Biomedical Engineering, Southern Illinois University, Carbondale, IL, USA.
Qingsheng LiHIV Cure and Viral Diseases Center, The Wistar Institute, Philadelphia, PA, USA.
Peter A CalabresiDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David VolskyDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Barbara S SlusherDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Atsushi KamiyaPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiaolei ZhuPsychoimmune Biology Program, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: xzhu31@jhmi.edu.

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Ahmet Hoke · 2006 to 2026
$33.2M
Project 3P50MH136297 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Akira Sawa · 2024 to 2026
$12.8M
Microglia-mediated adverse effect of cannabis on prefrontal cortex maturation and cognitive functionR01DA060630 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Atsushi Kamiya · 2025 to 2026
$1.4M
The role of microglial glutaminase in HIV-induced sleep deficitsR01HL180044 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Xiaolei Zhu · 2025 to 2026
$1.4M
Microglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depressionR56MH135895 · NIMH · JOHNS HOPKINS UNIVERSITY · PI ZHU, XIAOLEI · 2024 to 2025
$1.1M
Exploring a natural product to modulate aberrant gut bacterial-fungal interactions as pathological mechanisms underlying HIV-associated depressionK01AT010984 · NCCIH · JOHNS HOPKINS UNIVERSITY · PI ZHU, XIAOLEI · 2020 to 2024
$676k
NCCIH NIH HHS K01 AT010984NHLBI NIH HHS R01 HL180044NIDA NIH HHS R01 DA060630NIMH NIH HHS P30 MH075673NIMH NIH HHS P50 MH136297NIMH NIH HHS R56 MH135895
6 · The paper itself

Abstract

HIV-associated neuropsychiatric and neurocognitive disorders remain prevalent in people living with HIV (PWH) despite antiretroviral therapy (ART), underscoring the need for novel mechanistic insights and therapeutic strategies. Emerging evidence suggests that gut fungal dysbiosis contributes to neuroimmune dysfunction. Nevertheless, its contribution to HIV-associated psychosocial and cognitive deficits is poorly understood. Here, using the murine EcoHIV infection model that recapitulates key features of HIV neuropathogenesis, we identify a female-specific gut fungal signature associated with EcoHIV-induced psychosocial and cognitive impairments. Although EcoHIV infection induces behavioral impairments in both male and female mice, the present study identifies a distinct, female-associated mechanism involving gut Malassezia globosa enrichment and activation of a dectin-1

Indexed as

DysbiosisGastrointestinal MicrobiomeHIV InfectionsLectins, C-TypeMacrophagesMycobiomeAnimalsCognitive DysfunctionDectin-1Disease Models, AnimalFemaleMaleMiceMice, Inbred C57BLSex FactorsSignal TransductionDectin-1Lectins, C-TypeDectin-1EcoHIVGut mycobiomeMacrophagePsychosocial and cognitive deficitsβ-glucan

Identifiers

PMID41825652
PMCPMC13094659

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.